In this series, although patients receiving RM both after first and second induction therapy benefited from the treatment, longer treatment-free intervals and disease control were seen in the first line setting. The benefits of repeating Rituximab maintenance have not been prospectively evaluated; in countries where economic constraints impose restrictions to its repeated use, the results suggest that advanced FL patients should preferentially receive RM after first line.
Home / Resource Library / Rituximab Maintenance for Advanced Follicular Lymphoma (FL) Patients – Comparison of Outcomes after First and Second Line Treatment in a Single Center Series